Prostate Cancer

Achilles’ heel in lethal prostate cancer discovered

An international research team has discovered a genetic Achilles’ heel in neuroendocrine prostate cancer—a vulnerability that researchers say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers. » More

RANK ligand inhibitor delays development of PCa bone metastasis

Treatment with the RANK ligand inhibitor denosumab (XGEVA) is effective at delaying the development of bone metastases in men with nonmetastatic castration-resistant prostate cancer, according to a recent multicenter study. » More

CMS now covering prostate Ca immunotherapy infusion costs

Dendreon Corp. has announced that the Centers for Medicare & Medicaid Services has updated its coverage policy to now cover the infusion costs associated with the administration of the advanced prostate cancer immunotherapy sipuleucel-T (Provenge). » More

Sexual Dysfunction

ED increases with use of multiple medications

The use of multiple medications is associated with increased severity of erectile dysfunction, say researchers from Kaiser Permanente Los Angeles Medical Center. » More

Overactive Bladder

FDA sets target date for completing OAB drug review

Astellas Pharma, Inc, has announced the receipt of a letter from the FDA indicating that it accepted for filing the new drug application for mirabegron (YM178) and initiated a substantive review. » More

Survey

Are you seeing a rise in kidney stone incidence among your younger patients?

Yes
No
Not sure

Respond Here and see what your colleagues are saying.

Want to see the results of our last survey regarding the U.S. Preventive Services Task Force’s recommendations on PSA screening?
Click here.

New Job Opportunities

Bend Urology Associates, LLC		Ochsner Health System
Philadelphia Urology Assoc		Regional Urology
SUNY Upstate Medical University

Tools

•	Coding & Reimbursement
•	Legislative Updates
•	Events Calendar
•	AUA Clinical Guidelines
•	Cancer Nomograms
•	Rx Adherence Predictor

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.